Literature DB >> 8475410

Cellular pharmacodynamics of anticancer drugs.

W Plunkett1, V Gandhi.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8475410

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  10 in total

Review 1.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Biological effects of a relatively low concentration of 1-beta-D-arabinofuranosylcytosine in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

Authors:  H Yamada; J Horiguchi-Yamada; M Nagai; S Takahara; T Sekikawa; T Kawano; K Itoh; S Fukumi; S Iwase
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

Review 4.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

Review 5.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.

Authors:  Auke D Adema; Kees Smid; Nienke Losekoot; Richard J Honeywell; Henk M Verheul; Finn Myhren; Marit L Sandvold; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2011-10-15       Impact factor: 3.850

7.  Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.

Authors:  J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; C G Taylor
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

8.  Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.

Authors:  Auke D Adema; Karijn Floor; Kees Smid; Richard J Honeywell; George L Scheffer; Gerrit Jansen; Godefridus J Peters
Journal:  Springerplus       Date:  2014-12-13

Review 9.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

10.  Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.